peripheral neuropathy

(redirected from Peripheral Neuropathies)
Also found in: Medical.

peripheral neuropathy

n.
Neuropathy resulting from damage to the peripheral nervous system and characterized by symptoms such as numbness, burning, muscle weakness, and organ dysfunction. Peripheral neuropathy can be caused by physical trauma, a systemic disorder such as diabetes mellitus or peripheral vascular disease, or an autoimmune disorder.
Mentioned in ?
References in periodicals archive ?
The National Institute of Neurological Disorders and Stroke will provide four years of funding, totaling $1,219,140, to The Jackson Laboratory to develop mouse models for inherited peripheral neuropathies and neurodegenerative diseases including Charcot-Marie-Tooth disease (CMT).
EpiCept NP-1 is a topical analgesic cream containing two FDA-approved drugs, amitriptyline and ketamine, in development for the relief of pain from various peripheral neuropathies.
It is currently in development for the relief of pain from various peripheral neuropathies.
NP-1 is a prescription topical analgesic cream of two approved drugs, 4% amitriptyline and 2% ketamine, for long-term relief from the pain of peripheral neuropathies.
NRI), a biopharmaceutical company focused on treatments for peripheral neuropathies, has announced that its request for orphan drug designation of 4-Aminopyridine has been granted for treatment of chronic functional motor and sensory deficits resulting from Guillain-Barre Syndrome (GBS).
Peripheral neuropathies, foot numbness and pain, are frequent complaints in primary care, and the complexity of nerve anatomy and pathology often lead primary care providers to refer patients to neurologists, who are often challenged as well.
The Post is beginning to research the physiology and treatment of peripheral neuropathies.
Patients may describe the pain associated with peripheral neuropathies as dull, cold, burning, crushing, aching, cramping, or tingling.
EpiCept[TM] NP-1 is a patented topical cream formulation of two FDA- approved drugs, 4% amitriptyline and 2% ketamine, and is intended to provide long-term relief from the pain of peripheral neuropathies.
Approved Canadian labeling, based on submission of published clinical studies, includes: temporary reduction in disturbances in skin sensation, increases in balance and reduction in fall risk (when used adjunctively with physical therapy) due to diabetic and other peripheral neuropathies.
Among the nerve disorders claimed are spinal cord injury, amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's Disease), and peripheral neuropathies caused by injury or disease.
The neuregulins also have potential to be therapeutic in other acute or degenerative disorders of the CNS, such as SCI, peripheral neuropathies and Parkinson's disease.

Full browser ?